Baird 'Incrementally Negative' After Celgene (CELG) GED-0301 Data a Non-Event
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s Disease
September 12, 2016 7:30 AM EDTData show endoscopic improvement and clinical response and remission at week 12
Safety and tolerability consistent with previous studies
Results expected to be presented at upcoming medical meetings
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohns disease.
The trial, CD-001, is an ongoing study evaluating... More
Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Closing Bell
September 8, 2016 10:00 AM EDTADVISORY, Sept. 08, 2016 (GLOBE NEWSWIRE) --
What:Â Celgene Corporation (Nasdaq: CELG), an integrated global biopharmaceutical company, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Mark J. Alles, Chief Executive Officer, will ring the Closing Bell.Â
Where:Nasdaq MarketSite 4 Times Square 43rd & Broadway Broadcast Studio
When:Friday, September 9, 2016 3:45 p.m. to 4:00 p.m. ET Â
Celgene Media Contact:Brian Gill(908)... More
